Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. - Wikidata - wikimedia - TriplyDB

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

http://www.wikidata.org/entity/Q33586010

about

Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug An enzymatically activated fluorescence probe for targeted tumor imaging.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.Recent trends in targeted anticancer prodrug and conjugate design.Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.Targeted prodrug design to optimize drug delivery.Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat.Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood.A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging.Drug targeting with monoclonal antibodies. A review.Haemodynamic and transport barriers to the treatment of solid tumours.Development of antibodies for cancer therapy.Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data Antibody-enzyme fusion proteins for cancer therapy.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.ADEPT and related concepts.Review: advances in monoclonal antibody tumour targeting.Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis.Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model Targeting enzymes for cancer therapy: old enzymes in new roles.Strategies in antibody therapy of cancer.Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy.Alternative splicing as a novel of means of regulating the expression of therapeutic genes.Targeting enzymes to cancers--new developments.A universal antibody-derived targeting agent.Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial

P2860

Q24794696-02AE0F77-8973-4C37-9D3D-BEB083E7C0FD Q30483794-21F9DFA5-F7C2-4A21-94B5-13E88057A677 Q33230098-C4D8E168-8042-407E-907F-BBBCB9EEB575 Q33573762-97F9D6AA-6BCA-4F41-B193-7A556E8E6984 Q33580506-BB3A0221-87F8-48F9-9075-300B9E4AA5E1 Q34461985-CCA5E06D-62A8-4BC8-8C08-177F48945EBE Q34577226-437E50D3-D5BB-4319-9C85-6A7796600A0C Q35796256-56EE28B9-808E-4820-922A-8846673C1581 Q35851436-337B773A-3043-4358-AFBB-3C68F68DB756 Q35994452-1B1B0C20-1FA9-4329-A4C0-23CF4B0EE387 Q36081392-9B29A94C-9DA0-487A-9B16-2538BD4537C6 Q36314064-E3EF38E9-6223-47AF-A134-EE0FD0CCE221 Q36347866-DA0FA948-E506-4FE6-A392-98B1EF02C550 Q36351254-AC3AD207-0F9D-49C8-BACC-9C4C26B1A976 Q36509071-583155C2-94C8-4EAD-8ED2-E5F96E176EE4 Q36541958-8634A59A-6E22-4246-BF8C-F52AA6474347 Q36619067-4C318290-2A83-4CC6-94F9-30ED151E8E91 Q36795109-5F6D108E-3D53-44E9-A142-770584F34758 Q37842324-3DBC180A-18DE-4419-B713-14FC82CDE494 Q37854644-40E72D58-D231-49B2-9E31-135F7442DF1F Q38282674-3A24820D-363B-4128-9288-E3C5B4ED0695 Q38694283-16CF5DF6-1837-4ECD-AADF-35665DC8A2E4 Q38979784-0C733419-DE35-4648-9F8F-056074879807 Q40517119-FB18102B-32A9-4CDC-8DC4-10A4B7F8FF43 Q40694059-6BC14418-18A2-496F-9785-D06195332A0E Q40820608-31075972-51D1-4F7C-9F13-ABB620B33586 Q41507993-5F0603AE-B1CF-4D4A-948A-E36FAD3238E1 Q41831996-E09219C7-604D-4054-A43F-5215CD9C347C Q41931919-E55BDC00-4617-4AC3-9264-41980798F091 Q41936147-DBF31C6B-7E19-449D-960B-61EF5DE92FAA Q41965983-6EB0AFF4-E092-433F-AA1E-1509F27811DE Q42283385-67F2B92A-0C56-4BAE-8AB4-BC25F44B37DF Q42590388-D11B58E4-960D-4D61-BFFA-6F551F35791F Q43758820-CD965607-0862-4595-B1EB-30A8477777B1 Q43824475-9F9463B5-D7D5-49C8-B300-939B8BF980EE Q45714276-3CEC1AF4-BA8B-49D4-9737-09748F9D878B Q53619323-80226B44-4C20-4562-A642-F42CE0461B0A Q54665587-642BEC17-F6BC-4A15-A56C-07EB71F2811B Q56574975-9D376B73-038E-41B7-8BDF-C69DDE895C53

P2860

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

http://www.wikidata.org/entity/Q33586010

description

1988 nî lūn-bûn

@nan

1988 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1988 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1988年の論文

@ja

1988年論文

@yue

1988年論文

@zh-hant

1988年論文

@zh-hk

1988年論文

@zh-mo

1988年論文

@zh-tw

1988年论文

@wuu

name

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@ast

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@en

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@nl

type

label

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@ast

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@en

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@nl

prefLabel

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@ast

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@en

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@nl

P1433

Q33586010-04AEAE7B-7A8D-44CF-84AF-D979595F36C5

P1476

Q33586010-05FC42BD-F616-4196-841F-28CAF331F910

P2093

Q33586010-27DC9666-6182-4EB8-A323-D818EE77D1B0

Q33586010-296E2968-F087-45F5-B3BE-D066BF96F3AC

Q33586010-3EB1BDF4-2A89-4F2B-909A-08BA0E006C0B

Q33586010-5E2F2E86-E098-44AE-BD07-2643547E1547

Q33586010-AF9ED332-6EF7-4324-BFCD-EC013431F7BB

Q33586010-D5ED5B67-7F5A-4975-B650-9B55BD055D7E

Q33586010-F27C51EC-4A07-46EB-9897-A9A9635D6952

P2860

Q33586010-028276BC-3123-4904-A1AB-655FD434B684

Q33586010-258C8381-4EFE-4D60-A2B1-B53C9450D645

Q33586010-6D48FD1F-6766-4BA1-9898-3C0FE66ED586

Q33586010-B17790F6-2B71-4A52-8AE3-5346B4E084E8

Q33586010-BC3540DC-0013-40A5-BB06-F3C254AA0702

Q33586010-FAD5ADD5-36CA-408A-9160-C093C348AEE5

Q33586010-FF66ECAF-AC49-45D0-9E8D-DE803E85851C

P304

Q33586010-28B0C746-5F57-40DD-87D1-C11B16677BB2

P31

Q33586010-F4391FA2-AACA-4886-A218-B55FAB85ED07

P356

Q33586010-6923B160-6A02-4327-8730-673AF53B929F

P407

Q33586010-05A1AA40-D9EB-4288-B8E2-FA29A2C06927

P433

Q33586010-1352E6EA-A9E1-419F-859D-47F3045D3FC6

P478

Q33586010-03E767E1-946C-416E-9BEC-1AA2F1FE965E

P577

Q33586010-9766EDDD-1CC7-452E-B02C-6005527569F7

P5875

Q33586010-0DEB7E93-6256-42CE-957E-010C52CDCBDA

P698

Q33586010-0EE4BB82-E85B-4987-8E31-6B8A887F583C

P921

Q33586010-667890A3-DE3C-46FC-8834-6346603D43C0

P932

Q33586010-5C742480-3A9A-45C0-AC24-F636D51FA791

P356

PNAS.85.13.4842

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Anti-tumor effects of antibody ...... tion with etoposide phosphate.

@en

P2093

Brown JP

http://www.w3.org/2001/XMLSchema#string

Hellström I

http://www.w3.org/2001/XMLSchema#string

Hellström KE

http://www.w3.org/2001/XMLSchema#string

Hirschberg DL

http://www.w3.org/2001/XMLSchema#string

Saulnier MG

http://www.w3.org/2001/XMLSchema#string

Schreiber GJ

http://www.w3.org/2001/XMLSchema#string

Senter PD

http://www.w3.org/2001/XMLSchema#string

P2860

Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril

Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens

Role of the Bp35 cell surface polypeptide in human B-cell activation.

Etoposide (VP-16-213). Current status of an active anticancer drug.

Redesigning nature's poisons to create anti-tumor reagents.

In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody.

Monoclonal mouse antibodies raised against human lung carcinoma.

P304

4842-4846

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.85.13.4842

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

1988-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

19769774

http://www.w3.org/2001/XMLSchema#string

P698

3387440

http://www.w3.org/2001/XMLSchema#string

P921

P932

280532

http://www.w3.org/2001/XMLSchema#string